


Early microscope









Figure 1. Cellular Responses to External and Internal Signals














Figure 1. Cellular Responses to External and Internal Signals











Funktion / opførsel











Figure 1. Cellular Responses to External and Internal Signals


DNA → RNA








AMINOSYRE KÆDE














Immunocyology nålekoagel

- 1. Centrifuger materialet 10 min. ved 3000 omdr./min.
- 2. Hæld supernantanten fra.
- 3. Tilsæt 3 dråber humant plasma.
- 4. Opslem, med pipetten, forsigtigt bundfaldet i plasmaen.
- 5. Tilsæt 2 dråber thrombin. Dannes der ikke et koagel indenfor 1 minut; tilsæt 1 dråbe BT.
- 6. Tilsæt 4% neutralt bufferet formaldehyd.
- 7. Åben en gazepose, træk den over reagensglasset.
- 8. Hæld koaglet i gazeposen.
- 9. Læg posen i en kapsel med mikroskopi-nummeret.
- 10. Dryp et par dråber hæmatein på koaglet.
- 11. Læg kapslen i en bøtte med 4% neutralt buffet formaldehyd.












Mikroskopisk klassifikation, diagnose

#### Immuncytology








• Prædiktion

# Examples of PD-L1 IHC Staining of NSCLC Samples Using the Clinical Trial Assay




Brown chromogen: PD-L1 staining. Blue color: hematoxylin counterstain.


Garon\_AACR 2015\_19Apr15


#### • Prædiktion


PD-L1 IHC 28-8 pharmDx								
	Cutoff	Cutoff	Cutoff					
	≥ 1% positive	≥ 5% positive	≥ 10 %					
	cells	cells	positive cells					
Overall agreement	87 (80 – 94)	95 (91 – 99)	90 (83 – 95)					
Average Positive Agreement	86 (77 – 94)	94 (86 – 99)	84 (71 – 93)					
Average Negative Agreement	88 (80 – 94)	96 (92 – 99)	92 (87 – 97)					
Positive Percent  Agreement	81 (69 – 92)	91 (79 – 100)	79 (63 – 93)					
Negative Percent Agreement (NPA)	93 (85 – 100)	98 (94 – 100)	95 (88 – 100)					
Pearson R <sup>2</sup> of PD-L1 scores	0.89							


Guldhammer Skov

















#### Kan DNA extraheres fra cytologisk materiale?





FIGURE 3. Comparison of yields using fixation with isopropanol-based spray ("spray") or ethanol (EtOH) (90%) is shown. Cells were stained using the Papanicolaou method and Eco-Mount (Biocare Medical LLC, Concord, Calif) was used as the mounting medium. The means and the standard error of the mean from 2 batches with 3 replicates of each case are shown.




**FIGURE 4.** Comparison of yields are shown between 2 liquid-based methods and ethanol (EtOH) fixation, each with nominally 40,000 cells, stained with hematoxylin and eosin (HTX) and Papanicolaou (PAP) and with EcoMount (Biocare Medical LLC, Concord, Calif) used as the mounting medium. According to the manufacturer's instructions, precoated slides were used for cells in CytoRich Red, whereas routine slides were used for the other fixations.


Preparation of DNA From Cytological Material


Effects of Fixation, Staining, and Mounting Medium on DNA Yield and Quality

Kan DNA extraheres fra cytologisk materiale?












Kan DNA extraheres fra cytologisk materiale?

**TABLE 2.** Presence of Visible Bands of DNA Fragments in Extracts With Different Fixations (Median Value of 2 Batches With 3 Replicates Is Shown)<sup>a</sup>

Air				Spray				CytoRich Red				
Nominal Cell Count	209 bp	388 bp	578 bp	760 bp	209 bp	388 bp	578 bp	760 bp	209 bp	388 bp	578 bp	760 bp
5000	2	1	-1	-1	2	2	1	1	2	2	1	0
10,000	2	1	-1	-1	2	2	1.5	1	2	2	1	.5
20,000	2	1	-1	-1	2	2	2	2	2	2	1.5	.5
40,000	2	1.5	-1	-1	2	2	2	2	2	2	1.5	.5


Abbreviation: bp, base pair.


<sup>&</sup>lt;sup>a</sup> Scoring: strong band=2; distinct band=1; indefinite=0; no band=-1.




















Molekylær patologi





Prognostisk markør (risiko hos raske)
















Prediktiv markør



TC i prøven









EML<sub>4</sub>-ALK EGFR

CK<sub>7</sub>, CK<sub>5</sub>/6 ttf1, p40 PDL1


Morfo.




# Lung cancer research landscape – MoA group and phase




TC i prøven



#### Multibel biomarkør analyse



CK<sub>7</sub>, CK<sub>5</sub>/6 ttf1, p40 PDL1



Lungecancer

#### Er fremtiden molekylær?

#### Oncomine Comprehensive Assay\* Gene List

#### Gene list available to customers under CDA only

Hotspot genes, n=73 (hotspot coverage)

ľ	otopot gonoo,	11 70 (11010)	or oo rollag
	ABL1 AKT1 ALK AR ARAF BRAF BTK CBL CDK4 CHEK2	GNA11 GNAQ GNAS HNF1A HRAS IDH1 IDH2 IFITM1 IFITM3 JAK1 JAK2 JAK3 KDR KIT KNSTRN KRAS MAGOH MAP2K1	MYD88 NFE2L2 NPM1 NRAS PAX5 PDGFRA PIK3CA PPP2R1A PTPN11 RAC1 RAF1 RET RHEB RHOA SF3B1 SMO SPOP SRC STAT3 U2AF1 XPO1

CDS, n=26 (full gene)

,		(1011	9
AP(	0		
ΑTN	Λ		
BAF	21		
BR	CA1		
BR	CA2		
CDI	H1		
CDI	KN2	Α	
FΒ>	<w7< th=""><th></th><th></th></w7<>		
GA	ГАЗ		
MS	H2		
NF1	1		
NF2			
NO.	TCH	11	
PIK	3R1		
PTO	CH1		
PTE	ΞN		
RB′	1		
SM	AD4		
SM	ARC	B1	
STŁ	<11		
TET	Γ2		
TP5			
TSC			
TSC			
VHL	_		
WT	1		
			_

Copy gain, n=49

ACVRL1 AKT1 APEX1 AR ATP11B BCL2L1 BCL9 BIRC2 BIRC3 CCND1 CCNE1 CD274 CD44 CDK4 CDK4 CDK6 CSNK2A1 DCUN1D1 EGFR ERBB2 FGFR1 FGFR2 FGFR3 FGFR4 FLT3 GAS6	IGF1R IL6 KIT KRAS MCL1 MDM2 MDM4 MET MYC MYCL MYCN MYO18A NKX2-1 NKX2-8 PDCD1LG2 PDGFRA PIK3CA PNP PPARG RPS6KB1 SOX2 TERT TIAF1 ZNF217

Fusion drivers, n=22 (183 assays)

ALK RET ROS1 NTRK1 ABL1 AKT3 AXL **BRAF** CDK4 EGFR ERBB2 ERG ETV1 ETV4 ETV5 FGFR1 FGFR2 FGFR3 NTRK3 **PDGFRA PPARG** RAF1


**DNA Panel** 

\*For Research Use Only. Not for use in diagnostic procedures.

**RNA Panel** 



#### Er fremtiden molekylær?



#### Er fremtiden molekylær?



Cancer. 2017 Jan 13. doi: 10.1002/cncy.21812. [Epub ahead of print]

## Next-generation sequencing of liquid-based cytology non-small cell lung cancer samples.

Reynolds JP<sup>1</sup>, Zhou Y<sup>1</sup>, Jakubowski MA<sup>1</sup>, Wang Z<sup>1</sup>, Brainard JA<sup>1</sup>, Klein RD<sup>1</sup>, Farver CF<sup>1</sup>, Almeida FA<sup>2</sup>, Cheng YW<sup>1</sup>.

	Run 1	Run 2	Run 3	Run 4	Run 5	Run 6	Run 7	Mean	SE	95% CI
<i>PIK3CA</i> c.1633G>A, p.E545K	1504	1607	1414	1279	1223	1286	1798	1444.43	78.29	1290.99-1597.87
PIK3CA c.3140A>G, p.H1047R	1708	1911	1627	1643	1801	1770	2261	1817.29	82.62	1655.35-1979.22
EGFR c.2155G>A, p.G719S	2188	2592	1962	2149	2017	1619	2563	2155.71	129.30	1902.3-2409.13
BRAF c.1799T>A, p.V600E	1154	1862	1548	1746	1977	1895	2627	1829.86	169.43	1497.79-2161.93
KRAS c.38G>A, p.G13D	1320	2173	1421	1613	2494	2125	2992	2019.71	229.82	1569.27-2470.16
KRAS c.35G>A, p.G12D	1318	2171	1418	1610	2489	2123	2988	2016.71	229.58	1566.75-2466.68



Mikroskopisk klassifikation, diagnose

Malignitetsgradering (prognose)

Tumor udbredning (lokalt)

Metastasering (Lymfeknude + fjern)

Prognostisk markør (risiko hos raske)

Diagnostisks markør


Prognostisk markør (risiko hos syge)

Prediktiv markør

· Farmakodynamisk markør

Væv Væsker





- Malignitetsgradering (prognose)
- Tumor udbredning (lokalt)
- Metastasering (Lymfeknude + fjern)


Prognostisk markør (risiko hos raske)

- Di Ptisks markør
- Prognostis rkør (risiko hos syge)
- Prediktiv markør
- Farmakodynamisk markør


Væv Væsker


































ALK, RET, ROS1, and NTRK1 fusion transcripts, in addition to targets designed to detect 5' and 3' ALK gene expression

KRAS, EGFR, BRAF, PIK3CA, AKT1, ERBB2, PTEN, NRAS, STK11, MAP2K1, ALK, DDR2, CTNNB1, MET, TP53, SMAD4, FBX7, FGFR3, NOTCH1, ERBB4, FGFR1, FGFR2



Take home message



# Cytology Rocks

